Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2024-02-06 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
We are enclosing herewith the Certificate dated February 3, 2024 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming ....
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agents confirming compliance with dematerialization and securities listing requirements for the period 01.01.2024 to 31.01.2024. It is addressed to stock exchanges and signed by the company secretary. The document is short (3294 characters) and primarily serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or management discussion. It is a regulatory compliance filing related to securities and depository regulations. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement and certification rather than a financial report or other specific filing type.
2024-02-06 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of a share certificate. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 39(3), which pertains to share certificate loss and related disclosures. The content is an announcement of an event (loss of share certificate) and the company's intention to issue a Letter of Confirmation after formalities. The document is short (1660 characters) and does not contain financial data, management discussion, or detailed report content. It is not a financial report, earnings release, or management report. It is a regulatory announcement related to shareholding records and compliance disclosures. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-01-30 English
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR), 2015, we would like to inform you that the RTA of the Company, Integrated Registry Management Services Private ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of a share certificate. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and details about the lost share certificate and shareholder. The content is an announcement of a specific event related to share certificates, not a financial report, management change, or voting result. It does not contain financial data or results, nor is it a report or presentation. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-30 English
Board Meeting — ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Board Meeting to be held on 08-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Comp…
Regulatory Filings
2024-01-26 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board of Directors meeting scheduled for February 8, 2024, to consider and approve the unaudited financial results for the quarter ended December 31, 2023. It also mentions the closure of the trading window for insider trading compliance. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a notification about a future board meeting and the agenda, not the actual interim or quarterly report. The document length is short (1498 characters), and it serves as an announcement to the exchanges rather than a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification to the stock exchanges.
2024-01-25 English
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 ,inter alia, to consider and approve the Unaudited Financial ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board of Directors meeting scheduled for February 8, 2024, to consider and approve the unaudited financial results for the quarter ended December 31, 2023. It also mentions the closure of the trading window for insiders. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a notification about a future board meeting and the expected approval of quarterly results, not the results or report itself. The document length is short (1498 characters), and it serves as an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related notices that do not fit other categories.
2024-01-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.